Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MESO 
Mesoblast Ltd (MESO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: MESO (3-star) is a SELL. SELL since 3 days. Simulated Profits (-4.39%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 454.74% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.92B USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 3 | Beta 0.76 | 52 Weeks Range 9.36 - 22.00 | Updated Date 11/7/2025 |
52 Weeks Range 9.36 - 22.00 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -302.37% |
Management Effectiveness
Return on Assets (TTM) -5.37% | Return on Equity (TTM) -18.95% |
Valuation
Trailing PE - | Forward PE 454.55 | Enterprise Value 2119694134 | Price to Sales(TTM) 111.37 |
Enterprise Value 2119694134 | Price to Sales(TTM) 111.37 | ||
Enterprise Value to Revenue 123.25 | Enterprise Value to EBITDA -6.55 | Shares Outstanding 128293480 | Shares Floating 777251671 |
Shares Outstanding 128293480 | Shares Floating 777251671 | ||
Percent Insiders 5.09 | Percent Institutions 2.71 |
Upturn AI SWOT
Mesoblast Ltd
Company Overview
History and Background
Mesoblast Ltd was founded in 2004. It is an Australian-based regenerative medicine company developing allogeneic cellular medicines.
Core Business Areas
- Cell-Based Therapies: Developing and commercializing cell-based therapies for inflammatory diseases and oncologic/hematologic disorders.
- Revascor: A proprietary formulation of mesenchymal stromal cells (MSCs) for the treatment of acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
Leadership and Structure
Silviu Itescu is the CEO. The organizational structure includes research and development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Remestemcel-L (Revascor): An allogeneic mesenchymal stem cell (MSC) therapy targeting inflammatory conditions, including acute graft versus host disease (aGVHD) and acute respiratory distress syndrome (ARDS). The competitor is traditional steroids treatment and other biologics. Market share is negligible currently due to limited approvals.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by aging populations and the need for novel therapies. Regulatory hurdles and manufacturing complexities remain challenges.
Positioning
Mesoblast is a pioneer in allogeneic cell therapy. Its competitive advantage lies in its proprietary MSC platform technology.
Total Addressable Market (TAM)
The TAM for Mesoblast's target indications is estimated to be in the billions of dollars. Mesoblast is positioning itself by focusing on specific high-need segments.
Upturn SWOT Analysis
Strengths
- Proprietary MSC technology platform
- Advanced clinical programs
- Experienced management team
Weaknesses
- Regulatory hurdles and approval timelines
- High development costs
- Reliance on clinical trial outcomes
- Manufacturing complexities and scale-up challenges
Opportunities
- Expansion into new therapeutic areas
- Partnerships with pharmaceutical companies
- Regulatory approvals in key markets
- Increased awareness and adoption of cell therapies
Threats
- Competition from other regenerative medicine companies
- Failure of clinical trials
- Changes in regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
- CRIS
- BMY
- VRTX
Competitive Landscape
Mesoblast has a differentiated technology platform but faces competition from established pharmaceutical companies and other regenerative medicine firms. Success hinges on demonstrating clinical efficacy and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to pipeline development and clinical trial progress. Specific metrics require access to financial reports.
Future Projections: Future growth is contingent on regulatory approvals and commercialization success. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include focusing on clinical trial execution and strategic partnerships.
Summary
Mesoblast has a unique cell therapy platform and addresses unmet needs, but faces regulatory and financial hurdles. Clinical trial success and commercialization are key to its future. The company needs strategic partnerships to expand reach and financial stability for long-term growth. Navigating regulatory challenges effectively is crucial for moving their products to market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesoblast Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2015-11-13 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.mesoblast.com |
Full time employees 81 | Website https://www.mesoblast.com | ||
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.